Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aurinia Pharmaceuticals ( (AUPH) ) has issued an announcement.
Aurinia Pharmaceuticals announced positive results from a Phase 1 study of aritinercept (AUR200), showing robust and long-lasting reductions in immunoglobulins, supporting once-monthly dosing. The company plans to initiate clinical studies in at least two autoimmune diseases later this year, potentially enhancing its market position and offering new treatment options for autoimmune conditions.
The most recent analyst rating on (AUPH) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.
Spark’s Take on AUPH Stock
According to Spark, TipRanks’ AI Analyst, AUPH is a Outperform.
Aurinia Pharmaceuticals scores well due to its strong financial performance and positive earnings call insights. However, the technical analysis indicates potential resistance due to overbought signals, and the valuation suggests the stock may be overvalued. The company’s ability to maintain growth amidst patent and regulatory challenges will be crucial.
To see Spark’s full report on AUPH stock, click here.
More about Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a biopharmaceutical company focused on developing therapies for autoimmune diseases with high unmet medical needs. Notably, it introduced LUPKYNIS, the first FDA-approved oral therapy for adult patients with active lupus nephritis, and is developing aritinercept (AUR200) as a dual inhibitor for potential treatment of autoimmune diseases.
Average Trading Volume: 1,320,295
Technical Sentiment Signal: Buy
Current Market Cap: $1.17B
Find detailed analytics on AUPH stock on TipRanks’ Stock Analysis page.